AIM ImmunoTech’s CEO to Present at the Planet Microcap Showcase Virtual Investor Conference 2020
OCALA, FL / ACCESSWIRE / April 20, 2020 / AIM ImmunoTech Inc. (NYSE American:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of cancers, today announced that Chief Executive Officer, Thomas K. Equels is scheduled to present at the Planet Microcap Showcase 2020 on Wednesday, April 22 at 10:40 AM Eastern Time. Mr. Equels will be hosting the presentation and answering questions from investors.
To access the live presentation, please use the following information:
Planet MicroCap Showcase Virtual Investor Conference 2020
Date: Wednesday, April 22, 2020
Time: 10:40 AM Eastern Time; 7:40 AM Pacific Time
Webcast: https://www.webcaster4.com/Webcast/Page/2059/34145
If you would like to book 1on1 investor meetings with AIM ImmunoTech, please make sure you are registered for the virtual event here: https://www.planetmicrocapshowcase.com/signup
1on1 meetings will be scheduled and conducted via private, secure video conference through the conference event platform.
If you can’t make the live presentation, all company presentations “webcasts” will be available directly on the conference event platform on this link under the tab “Schedule”: https://www.planetmicrocapshowcase.com/presenting-companies
News Compliments of Accesswire
About Planet MicroCap Showcase
Planet MicroCap Showcase brings together promising companies with well-known and influential microcap, investors, fund managers and newsletter writers for three days of company presentations, one-on-one meetings, and networking.
If you would like to attend the Planet MicroCap Showcase, please register here: https://planetmicrocapshowcase.com/signup
About AIM ImmunoTech Inc
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of cancers. AIM’s flagship products include the Argentina-approved drug rintatolimod (trade names Ampligen® or Rintamod®) and the FDA-approved drug Alferon N Injection®. Based on results of published, peer-reviewed pre-clinical studies and clinical trials, AIM believes that Ampligen® may have broad-spectrum anti-viral and anti-cancer properties. Clinical trials of Ampligen® include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. These and other potential uses will require additional clinical trials to confirm the safety and effectiveness data necessary to support regulatory approval and additional funding. Rintatolimod is a double-stranded RNA being developed for globally important debilitating diseases and disorders of the immune system.
Cautionary Statement
Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For example, significant additional testing and trials will be required to determine whether Ampligen will be effective in the treatment of COVID-19 in humans and no assurance can be given that it will be the case. Results obtained in animal models do not necessarily predict results in humans. Human clinical trials will be necessary to prove whether or not Ampligen will be efficacious in humans. Some of the world’s largest pharmaceutical companies and medical institutions are racing to find a treatment for COVID-19. Even if Ampligen proves effective in combating the virus, no assurance can be given that our actions toward proving this will be given first priority or that another treatment that eventually proves capable will not make our efforts ultimately unproductive. Neither can any assurances be made as to any future immuno-oncology clinical trials related to the matter herein. No assurance can be given as to whether the current or planned trials will be successful or yield favorable data and the trials are subject to many factors including lack of regulatory approval(s), lack of study drug, or a change in priorities at the institutions sponsoring other trials. In addition, initiation of planned clinical trials may not occur secondary to many factors including lack of regulatory approval(s) or lack of study drug. Even if these clinical trials are initiated, we cannot assure that the clinical studies will be successful or yield any useful data or require additional funding. Among other things, for forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at www.aimimmuno.com. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.
Contacts:
Crescendo Communications, LLC
Phone: 212-671-1021
Email: aim@crescendo-ir.com
AIM ImmunoTech Inc
Phone: 800-778-4042
Email: IR@aimimmuno.com
SOURCE: AIM ImmunoTech via Planet MicroCap Showcase
View source version on accesswire.com:
https://www.accesswire.com/585617/AIM-ImmunoTechs-CEO-to-Present-at-the-Planet-Microcap-Showcase-Virtual-Investor-Conference-2020
